Replies to post #191181 on Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

"Research of a human xenograft animal model of psoriasis conducted by Cellceutix on KM-133 measuring it against methotrexate, a commonly used drug today in the treatment of psoriasis, showed a faster reduction of lesion appearance (84% versus 63%), a greater reduction in serum PRINS (96 versus 48%) and a significant reduction in serum IL-20 (87% versus 46%) in models treated with KM-133 as compared to methotrexate. More importantly, psoriasis lesions showed no reoccurrence in models treated with KM-133 throughout the 180-day study whereas psoriasis lesions reappeared in those treated with methotrexate in 61 days."

http://www.ipharminc.com/press-release/2016/11/17/cellceutix-to-pursue-505b2-clinical-process-for-psoriasis-drug

I think I remember someone on here showing a good relationship between their pre-clinical process results and potential clinical results (likely from studies on other psoriasis drugs). I'd like to look into that again, but I can't find it!

[williamssc]

Yes seems they removed preclinical mouse studies off their website. I wish they would add it back. The following link containes preclinical slides. Just click inside the box.

http://slideplayer.com/slide/219787/1/images/14